Kura Oncology (NASDAQ:KURA) Trading 5% Higher - What's Next?

Key Points

• Kura Oncology shares rose 5% to $8.35, despite a significant drop in trading volume, suggesting volatility in market interest.
• Analysts maintain a consensus rating of "Moderate Buy" for Kura Oncology, with a range of price targets from $24.00 to $36.00 following recent research reports.
• The company's recent earnings report showed a loss of ($0.75) EPS, significantly missing expectations, with revenue at $15.29 million compared to the estimated $64.95 million.

Shares of Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) rose 5% during mid-day trading on Wednesday . The company traded as high as $8.41 and last traded at $8.35. 327,215 shares changed hands during trading, a decline of 78% from the average daily volume of 1,457,807 shares. The stock had previously closed at $7.95.

Wall Street Analyst Weigh In

KURA has been the topic of a number of research reports. Wedbush restated an "outperform" rating and issued a $36.00 price target on shares of Kura Oncology in a report on Friday, June 20th. JMP Securities decreased their target price on Kura Oncology from $28.00 to $24.00 and set a "market outperform" rating on the stock in a research report on Monday, August 11th. Wall Street Zen upgraded Kura Oncology from a "sell" rating to a "hold" rating in a research report on Sunday, August 17th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Kura Oncology in a research report on Thursday, June 26th. Finally, Mizuho cut their target price on shares of Kura Oncology from $32.00 to $30.00 and set an "outperform" rating for the company in a research report on Monday, May 19th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and three have given a Hold rating to the company. According to MarketBeat, Kura Oncology has a consensus rating of "Moderate Buy" and an average price target of $24.10.

Kura Oncology Stock Performance

The stock has a market cap of $726.08 million, a price-to-earnings ratio of -3.70 and a beta of 0.19. The company has a current ratio of 6.16, a quick ratio of 6.16 and a debt-to-equity ratio of 0.02. The stock's 50-day moving average is $6.51 and its 200-day moving average is $6.57.

Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.90). The company had revenue of $15.29 million during the quarter, compared to analyst estimates of $64.95 million. On average, analysts expect that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. State of Wyoming bought a new stake in shares of Kura Oncology in the 1st quarter worth $48,000. Pallas Capital Advisors LLC acquired a new position in shares of Kura Oncology in the 1st quarter worth $66,000. Tower Research Capital LLC TRC lifted its holdings in shares of Kura Oncology by 471.3% during the second quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company's stock valued at $70,000 after purchasing an additional 9,958 shares during the last quarter. Flower City Capital acquired a new position in shares of Kura Oncology in the 1st quarter valued at $79,000. Finally, Magnetar Financial LLC purchased a new position in Kura Oncology in the 1st quarter worth about $79,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.